RE ENDOTHELIALIZATION AND RESTENOSIS

$294,732R01FY2000HLNIH

Caritas St. Elizabeth'S Medical Center, Boston MA

Investigators

Linked publications, trials & patents

Paper 26882996 Paper 23375595 Paper 23204107 Paper 23197763 Paper 23192920 Paper 22941227 Paper 22581926 Paper 22330336 Paper 22048734 Paper 21896844 Paper 21835908 Paper 21808036 Paper 21658566 Paper 21566217 Paper 20888519 Paper 20534467 Paper 20478312 Paper 20203265 Paper 20176991 Paper 20144623 Paper 19815827 Paper 19752322 Paper 19635599 Paper 19436808 Paper 19298964 Paper 19144777 Paper 19118717 Paper 19115244 Paper 18755197 Paper 18591450 Paper 18510483 Paper 18206807 Paper 17950369 Paper 17942950 Paper 17656679 Paper 17562958 Paper 17395877 Paper 17392158 Paper 17261656 Paper 17164777 Paper 17088460 Paper 17075009 Paper 16835303 Paper 16702471 Paper 16534014 Paper 16501618 Paper 16484619 Paper 16401693 Paper 16342193 Paper 16244652 Paper 15965500 Paper 15897348 Paper 15067321 Paper 14676142 Paper 12860919 Paper 12628955 Paper 12551872 Paper 12409255 Paper 12160849 Paper 12081997 Paper 11795425 Paper 11532899 Paper 11506696 Paper 11342572 Paper 11156872 Paper 11133594 Paper 10864908 Paper 10836914 Paper 10742147 Paper 10725398

Abstract

DESCRIPTION (adapted from the applicant's abstract): The hypotheses to be tested in each case have been organized according to the following three Specific Aims. Specific Aim #1: To investigate the potential for endothelial cell (EC) mitogens to accelerate re-endothelialization (rET); Specific Aim #2: To investigate certain mechanisms by which EC mitogens facilitate rET; and Specific Aim #3: To investigate augmented rET using EC precursors isolated from peripheral blood. The studies will be performed in vitro and in vivo. The latter will include a hyperlipidemic rabbit model of double-balloon injury, and, in selected cases, rat and mouse models of single and/or double-balloon injury. Experiments in Specific Aim #1 are expected to define, short of human studies, the potential for EC mitogens to effectively modulate pathologic alteration of the artery wall. Experiments from Specific Aim #2 are expected to elucidate the role of vascular endothelial growth factor (VEGF) as a previously unappreciated endogenous regulatory factor responsible for maintaining and restoring the integrity of the vascular endothelium. Experiments form Specific Aim 3 are considered by the applicant to constitute a "supply side" strategy that will consider circulating EC precursors as penultimate ECs that may be used in conjunction with EC mitogens to augment rET.

View original record on NIH RePORTER →